{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-026761","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2026-06-02T12:10:25+00:00","discovered_at":"2026-06-02T12:15:00.454990+00:00","generated_at":"2026-06-02T12:15:29.188266+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gedatolisib doubles PFS vs alpelisib in PIK3CA mutant HR+/HER2- ABC Phase 3 trial","bullets":["Gedatolisib-triplet reduced risk of progression or death by 50% (HR=0.50; p<0.0001); median PFS 11.1 vs 5.6 months.","ORR 48.9% for triplet vs 26.0%; median DOR 15.7 vs 7.5 months for alpelisib+fulvestrant.","Grade 3+ TRAEs: neutropenia 58.8% (triplet) vs 0.7%; discontinuation rate 2.6% vs 7.1%.","Company plans sNDA submission following positive PIK3CA MT cohort; PDUFA for NDA in WT cohort July 17, 2026.","Commercial launch expected in Q3 2026 pending FDA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026761","json":"https://secwatch.observer/filing/0001493152-26-026761.json","markdown":"https://secwatch.observer/filing/0001493152-26-026761.md","text":"https://secwatch.observer/filing/0001493152-26-026761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315226026761/0001493152-26-026761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315226026761/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:15:29.188266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0000798359-26-000057","ticker":"CSR","company_name":"CENTERSPACE","filed_at":"2026-06-01T20:30:13+00:00","headline":"Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000798359-26-000057","json":"https://secwatch.observer/filing/0000798359-26-000057.json","markdown":"https://secwatch.observer/filing/0000798359-26-000057.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/0000798359-26-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/iret-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251399","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-06-01T20:05:32+00:00","headline":"IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251399","json":"https://secwatch.observer/filing/0001193125-26-251399.json","markdown":"https://secwatch.observer/filing/0001193125-26-251399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/0001193125-26-251399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/d138848d8k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-252718","ticker":"QMCO","company_name":"QUANTUM CORP /DE/","filed_at":"2026-06-02T14:41:23+00:00","headline":"Quantum raises $100M equity, converts all convertible notes to equity; Q4 revenue above guidance","event_type":"other_material","sec_items":["1.01","2.02","2.03","3.02","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252718","json":"https://secwatch.observer/filing/0001193125-26-252718.json","markdown":"https://secwatch.observer/filing/0001193125-26-252718.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/709283/000119312526252718/0001193125-26-252718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/709283/000119312526252718/d35173d8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063832","ticker":"USAR","company_name":"USA Rare Earth, Inc.","filed_at":"2026-06-02T13:14:30+00:00","headline":"USA Rare Earth selects South Carolina for $1.2B magnet facility; 490 jobs, 6,400 tpa capacity","event_type":"other_material","sec_items":["1.01","2.03","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063832","json":"https://secwatch.observer/filing/0001213900-26-063832.json","markdown":"https://secwatch.observer/filing/0001213900-26-063832.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1970622/000121390026063832/0001213900-26-063832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1970622/000121390026063832/ea0293127-8k_usarare.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-069246","ticker":"SHAK","company_name":"Shake Shack Inc.","filed_at":"2026-06-02T12:06:18+00:00","headline":"Shake Shack cuts Q2 revenue guidance to $415-420M, same-shack sales to 2.5-3.0%","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069246","json":"https://secwatch.observer/filing/0001104659-26-069246.json","markdown":"https://secwatch.observer/filing/0001104659-26-069246.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620533/000110465926069246/0001104659-26-069246-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620533/000110465926069246/tm2616608d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-069206","ticker":"RZLT","company_name":"Rezolute, Inc.","filed_at":"2026-06-02T11:05:59+00:00","headline":"Rezolute reports positive interim Phase 3 upLIFT data: 6 of 8 patients met primary endpoint","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069206","json":"https://secwatch.observer/filing/0001104659-26-069206.json","markdown":"https://secwatch.observer/filing/0001104659-26-069206.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926069206/0001104659-26-069206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926069206/tm2616579d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0002007587-26-000071","ticker":"AII","company_name":"American Integrity Insurance Group, Inc.","filed_at":"2026-06-01T20:31:10+00:00","headline":"American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002007587-26-000071","json":"https://secwatch.observer/filing/0002007587-26-000071.json","markdown":"https://secwatch.observer/filing/0002007587-26-000071.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007587/000200758726000071/0002007587-26-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007587/000200758726000071/aii-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}